GSK2879552 dihydrochloride an orally active, selective and irreversible inhibitor of lysine specific demethylase 1 (LSD1/KDM1A), with potential antineoplastic activity.
体外研究
GSK2879552 inhibits KDM1A histone demethylase activity, inducing differentiation of sorafenib-resistant cells and attenuates stemness properties. GSK2879552 depresses the transcription of Wnt antagonists and downregulates β-catenin signaling activity in sorafenib-resistant cells.
Cell Viability Assay.
Cell Line:
9/28 small cell lung carcinoma (SCLC) lines and 20/29 AML lines.
Concentration:
0-10000 nM.
Incubation Time:
6 days.
Result:
Inhibited cell proliferation.
RT-PCR.
Cell Line:
Resistant HCC cells (PLC/PRF/5 and Huh7).
Concentration:
0, 1, 2 μM.
Incubation Time:
24 h.
Result:
Displayed reduced mRNA expression levels of stem cell markers, such as Lgr5, Sox9,
Nanog and CD90, and elevated mRNA expression levels of differentiation markers Alb and Hnf4.
There was 57% and 83% tumor growth inhibition (TGI) in NCI-H526 and NCI-H1417 tumor bearing mice respectively. NCI-H510 and NCI-H69 tumor bearing mice also demonstrated partial TGI (38% and 49% respectively) in response to GSK2879552, while no significant TGI was observed for SHP77 bearing mice.
分子式
C23H28Cl2N2O2
分子量
437.40
CAS号
1902123-72-1
运输条件
Room temperature in continental US; may vary elsewhere.